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Abstract 
Relationships between industry and university-based researchers have been commonplace for decades and have 
received notable attention concerning the conflicts of interest these relationships may harbor. While new efforts are 
being made to update conflict of interest policies and make industry relationships with academia more transparent, 
the development of broader institutional partnerships between industry and academic health centers challenges 
the efficacy of current policy to effectively manage these innovative partnerships. In this paper, we argue that exist-
ing strategies to reduce conflicts of interest are not sufficient to address the emerging models of industry-academic 
partnerships because they focus too narrowly on financial matters and are not comprehensive enough to mitigate 
all ethical risk. Moreover, conflict-of-interest strategies are not designed to promote best practices nor the scientific 
and social benefits of academic-industry collaboration. We propose a framework of principles and benchmarks for 
“ethically credible partnerships” between industry and academic health centers and describe how this framework may 
provide a practical and comprehensive approach for designing and evaluating such partnerships.
Keywords: Academic-industry partnerships, Collaboration, Ethics, Benchmarks, Cooperative behavior, Academic-
industry relationships, Conflict of interest, Academic health centers, Industry
© 2015 Meslin et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Industry has provided support for research by univer-
sity-based investigators for decades [1, 2], and from the 
earliest days of industry-academic collaboration, federal 
regulators and professional associations have sought to 
address the potential for conflict of interest by develop-
ing policies that would minimize the risk of bias due to 
decreased scientific objectivity that has tainted some 
academic faculty who partnered with companies [3]. The 
level of scrutiny for clinicians and investigators has never 
been greater than it is now, as evidenced by: tougher 
rules for accrediting continuing medical education 
programs [4]; specific provisions in the Affordable Care 
Act that require corporate sponsors and hospitals to 
report the funding physicians receive from industry 
research grants [5]; disclosure requirements by journals 
[6]; guidelines developed by professional associations [7]; 
and more structured financial disclosure systems such 
as the Association of American Medical Colleges’ “Con-
vey” program [8]. Like many Academic Health Centers 
(AHCs) in the US, our university has engaged in robust 
discussions on conflict of interest issues, the most recent 
of which was a thorough revision to Indiana University 
School of Medicine’s “Industry Relations Policy” [9]. Like 
most AHC policies, Indiana University’s was developed 
in light of the current emphasis on disclosing potential 
conflicts, restricting participation in speaker’s bureaus, 
limiting access to industry representatives, and setting 
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expectations regarding compensation for meals, travel, 
and publication and related matters [10, 11].
Yet, as worrisome as financial conflicts of interest by 
individual researchers may be, and as valuable as such 
guidance will most certainly be, these restrictions need to 
be framed against a countervailing force that is becom-
ing more common within the AHC environment: the 
active development and encouragement of AHC-industry 
research partnerships (AHCIP) and the innovative struc-
tures these partnerships might take. Medical schools are 
increasingly encouraging their research faculty to pur-
sue entrepreneurial strategies, to start companies and to 
partner actively with industry [11–13].
The rationale for this emphasis is clear. By leveraging 
the more than $68 billion of research funding by indus-
try [14], these efforts may accelerate research and lower 
the barriers to developing marketable medicines and 
other technologies which is ostensibly the central mis-
sion of translational science [15]. Indeed, the country’s 
premier public biomedical research sponsor, the National 
Institutes of Health, ventured further into this territory 
[16] in 2014 when it launched its Accelerating Medicines 
Partnership (AMP) involving 10 major biopharmaceuti-
cal companies in its initiative “to transform the current 
model for developing new diagnostics and treatments 
by jointly identifying and validating promising biological 
targets for therapeutics…[and] to increase the number of 
new diagnostics and therapies for patients and reduce the 
time and cost of developing them” [17].
More recently, a high profile and somewhat conten-
tious discussion has played out in major medical journals 
about whether current conflict of interest policies create 
an unnecessary and undesired chill of collaboration [18, 
19]. This discussion has highlighted the persistent ten-
sion between the imperative to danger that conflicts of 
interest will undermine and taint medical research and 
the imperative to harness all available tools to translate 
research into ways that combat disease and help patients. 
Our project aimed to balance these two key issues by 
establishing a clear process and set of guidelines to evalu-
ate steps taken to control conflicts of interest while also 
allowing robust and hopefully productive collaboration.
Common and emerging AHCIP models
The push towards more collaborative research between 
industry and academic researchers has generated innova-
tive approaches to structuring and managing the formal 
relationships between the respective organizations. His-
torically, the typical arrangement involved a private firm, 
such as a pharmaceutical company, providing a grant or 
contract to an academic investigator to conduct a tar-
geted study or pursue a line of research that is of inter-
est to the company and also falls within the scientific 
interests and expertise of the investigator. Indeed, a 
recent study confirmed that this popular structure con-
tinues to persist: the most common type of industry 
grant supports conventional clinical trials of new drugs 
or indications, and the most common arrangement is the 
use of unrestricted grants and fee-for-service structures 
to clinician-scientists in AHCs [20]. Many examples of 
these arrangements exist [1, 21].
However, newer types of AHCIPs are emerging that 
diverge from this model and use collaborative arrange-
ments to jointly pursue broad areas of research, data 
analysis or drug development [12, 21]. Such arrange-
ments may include: corporate venture capital funds, 
academic drug discovery centers, university consortia, 
competitive grant processes, and risk sharing [20, 22]. As 
just one example, in 2012, The Regenstrief Institute, Inc. 
(RI)–a health services research organization in Indian-
apolis affiliated with the IU School of Medicine–entered 
into a 5-year partnership with a large multinational phar-
maceutical company the goal of which was to improve 
“the health of patients through data analytics, health 
care innovation, education and research that supports 
evidence-based health care” [22]. Rather than sponsor-
ing one or more projects or researchers, this partnership 
established a process where a steering committee com-
prised of both RI and industry representatives sets annual 
research priorities and then solicits, reviews, and selects 
diverse research proposals to be funded according to 
pre-agreed criteria [22]—a process that has certain simi-
larities to the proposal submission and review selection 
procedures used for government research grants. Essen-
tial to submitting a proposal and being funded is that the 
project must be co-led by a university investigator and 
an industry scientist. Arrangements like these differ in 
substantive ways from the more traditional grant-sup-
ported-investigator model in terms of study duration, 
financial structure, expectations of reciprocal benefit, 
publishing results, and potential for broad impact at both 
organizations.
A need for a new tool: evaluating the ethics 
of AHCIPs
The structural differences between the traditional model 
and these emerging collaborative AHCIPs suggest that 
while financial disclosures may be a necessary starting 
point to identify, assess, and ameliorate potential con-
flicts of interest and related ethical issues, they are no 
longer sufficient to address the issues unique to part-
nerships. However, while the emerging AHCIP model 
may place a gap between industry money and individual 
investigators, possibly rendering conflict of interest dis-
closure policies less useful, this does not address the per-
ception that the involvement of industry with academic 
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institutions may pose more pernicious threats to values 
that AHCs represent and the trust that the public places 
in them [3, 19].
The emerging AHCIP model would then appear to 
challenge both the ethical rationale for current conflict of 
interest policies and the efficacy of current ethical tools 
for evaluating the relationships themselves. For example, 
in the traditional model, the principal ethics emphasis is 
to adequately manage and reduce both the risk of inves-
tigator bias in the conduct and reporting of research and 
the undue influence exerted by the prospect of profit-
ing from industry support [23]. Most efforts that seek to 
minimize this risk aim to eliminate the conflict by pro-
hibiting investigators from accepting industry funds or 
by requiring disclosure and management plans [3].
In the emerging AHCIP model however, the ethics 
emphasis is not solely limited to reducing the risk of bias, 
but also includes enhancing the positive benefits of the 
partnerships while mitigating other ethical risks. This 
aspect of AHCIPs can be best accomplished by anticipat-
ing potential ethical issues early in the construction of 
the partnership.
While much progress is being made to fine-tune guid-
ance for AHC-based investigators to better manage the 
risk of conflict of interest, comparably less progress has 
been made in developing an ethics-based approach to 
anticipating and addressing the suite of issues that arise 
in the emerging models of AHCIPs. In March 2013, we 
were asked to review an AHCIP and design such a frame-
work. The Regenstrief Institute (RI), Inc., contracted 
with the Indiana University Center for Bioethics (IUCB) 
to assess the RI component of their AHCIP and provide 
substantive, actionable recommendations to minimize 
the risk of potential or actual conflicts of interest and 
address other ethical issues. A key outcome was that the 
proposed work would be widely shared to allow discus-
sion and critique.
An ethics assessment of an innovative AHCIP
We began with two presumptions. First, we were open-
minded about the potential for AHCIPs to satisfy a set 
of accepted ethical standards. This alone was controver-
sial, as there is considerable opposition within the bio-
ethics and science communities about this idea. Some 
consider the very notion of industry collaboration with 
a university to be ethically untenable at best, and ethi-
cally forbidden at worst [23–25]. We reserved judg-
ment. Second, we knew from the outset that no ethics 
assessment could occur without a framework that was 
both philosophically sound and practically implementa-
ble. The Holy Grail in this case would be an approach 
to AHCIPs that maximizes the reciprocal science and 
research goals of both organizations while meeting (or 
exceeding) the highest levels of external ethical scrutiny. 
Arrangements that satisfy or demonstratively seek to 
satisfy these two features we refer to as “ethically cred-
ible partnerships.”
If they are to be useful to broader audiences, ethi-
cal frameworks to guide AHCIPs must go beyond 
basic abstract principles. Ethics principles are often 
used in health and science as general action guides for 
generating ethical policies [26]. Nonetheless, stand-
alone principles do not provide guidance for specific 
situations without some degree of interpretation, and 
disagreements often arise at this stage of application. 
Approaches that are intended to be more systematic 
have been developed include: checklists, practice guide-
lines [27], points to consider [28, 29], and benchmarks 
[30, 31]—all of which are more granular and hence 
less abstract and more applicable to individual cases 
than principles alone and thus may serve as achievable 
metrics.
Benchmarking for ethics content is a recent addition 
to the suite of planning and evaluation tools in health 
and science. Norman Daniels employed benchmarks in 
health care reform that have been widely discussed and 
used for policy guidance [32, 33]. Similarly, Emanuel 
et al. developed an ethics framework that combines prin-
ciples and benchmarks to assess the ethical acceptability 
of clinical trials in developing countries [30], an approach 
also embraced by others [34].
We foresaw a unique value to creating ethical bench-
marks for AHCIPs. They would (1) establish a practical 
and achievable floor for academic-industry partnerships; 
(2) provide more direct guidance than principles alone; 
(3) allow considerable freedom to accommodate the vari-
ous ways an individual benchmark may be achieved; (4) 
enhance AHCIP ethics reviews that go beyond financial 
conflicts of interest; and (5) enable a holistic approach to 
prospectively assess progress and identify possible defi-
ciencies so processes and outcomes can be improved. 
We also intended for this to be an early test of a proof-
of-principle for an alternative approach to evaluating 
AHCIPs beyond conflicts of interest.
Creating the principles and benchmarks
Our process for creating the principles and benchmarks 
of ethically-credible AHCIPs involved the reviewing key 
partnership documents; reviewing the relevant academic 
literature; scoping the issues; and developing and vetting 
the draft Principles and Benchmarks before producing a 
final document. Some commentary on the nature of the 
Regenstrief AHCIP has been recounted elsewhere which 
gives an account for how the Principles and Benchmarks 
were applied [22, 35]. Here we offer a slightly fuller 
account of these steps.
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1. Key document review After completing a Confi-
dentiality Agreement, we reviewed key documents 
including the Master Collaboration Agreement, an 
internally-produced investigator’s guide to the part-
nership, and an internal report of a survey of investi-
gator and staff experiences.
2. Literature review We conducted several literature 
reviews on ethical issues in academic-industry col-
laborations in September 2013. These papers were 
identified from the published literature using the 
OVID Medline Medical Subject Headings (MeSH 
terms): Industry AND Academies and Institutes/or 
Universities AND Cooperative Behavior AND Ethics, 
and from Google Scholar and PubMed using simi-
lar keywords. No filters regarding country of origin 
were used. Collectively, these searches resulted in 
63 papers which were retrieved, read, and analyzed 
for eligibility. Papers were excluded if they did not 
address or report on ethical issues, best practices, 
challenges, or exemplary models of academic-indus-
try partnerships. This process resulted in 29 papers.
3. Scoping issues The team met weekly from October 
2013 to December 2013. Each investigator had read 
the partnership documentation and was assigned 
a designated set of the retrieved papers to better 
determine their usefulness for creating the bench-
marks, looking specifically for exemplars, best prac-
tices, challenges, and suggestions for improving aca-
demic-industry partnerships. Discussion of all papers 
occurred with the entire team to reduce the risks of 
people with different backgrounds extracting differ-
ent meaning from the same text [36]. All papers were 
annotated and compiled into a bibliography available 
online [37].
4. Developing and vetting the principles and benchmarks 
Following the scoping exercise, all items were trans-
formed into an initial set of 60 benchmarks which we 
then separated into categories based on relatedness 
amongst their content. These categories were named 
and became an initial set of principles which we con-
tinually refined through an iterative process.
These principles provided the moral foundation for our 
benchmarking framework. All appear in various forms in 
the literature. The team agreed that the principles should 
be distinct and action guiding, and less abstract than 
other well-known bioethics principles such as respect for 
persons, beneficence, nonmaleficence and justice [26]. 
In their totality we intended for the principles to be suf-
ficient to help AHCs answer the question: what are the 
actions or policies that ethically-credible AHCIPs ought 
to take? The final list included 9 principles of ethical 
credibility:
  • Academic freedom This principle substantiates the 
ability of researchers to pursue their independent 
interests as they see fit [38, 39]. This principle may 
be satisfied if the partnership both promotes inves-
tigator-initiated science regardless of funding source, 
and protects investigators’ from being coerced into 
conducting research they are not comfortable pur-
suing. Additionally, the partnership ought to permit 
investigators to initiate or continue collaboration 
with any other qualified group, person, or entity and 
ensure that investigators involved in the partnership 
are given equal opportunity to submit proposals for 
funding.
  • Conflict of interest policy and management This prin-
ciple is meant to justify actions which seek to reason-
ably control the competing or potentially compet-
ing interests and commitments of involved parties 
and persons [40–45]. Managing such conflicts can 
be achieved through establishing tested methods for 
assessing potential conflicts of interests. A partner-
ship should also protect students, post-doctoral fel-
lows, and junior faculty involved in partnership pro-
jects from exploitation.
  • Data sharing and access This principle highlights 
the growing importance and use of ‘big data’, health 
informatics and database research. [2, 46–48] As 
such AHCIPs should create mutually agreed upon 
procedures for accessing each partner’s data and 
other relevant clinical information in order to facili-
tate research.
  • Intellectual property This principle addresses the 
need to protect the property rights of each partner 
and investigator that predate the partnership or arise 
from work conducted within it [2, 46–48].
  • Effective governance This principle addresses legal 
issues, administrative duties/obligations, and priority 
setting and fosters fairness, cooperation, and com-
munication within the partnership [38, 46, 48–50]. 
Effective governance should be structured in a way 
that enables research and is minimally burdensome. 
An ethically credible partnership that exhibits the 
principle of Effective Governance would establish 
parameters for what type of projects will and will not 
be funded; create ways to protect each party from a 
unexpected end to the partnership; formally assess 
the efficiency, effectiveness, and achievements of the 
partnership on an annual basis; and ensure that clear, 
comprehensive and efficient procedures exist for all 
governance entities of the partnership and that these 
are known to all investigators.
  • Protection of human subjects This principle has been 
the central justification for the system of oversight of 
research in the US and in other countries. Its most 
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salient method of ensuring protection has been the 
use of ethics review bodies, known in the US as IRBs. 
[51]. This principle binds partners to a commit-
ment to jointly comply with relevant domestic and 
international requirements for biomedical, behavio-
ral, epidemiological, and health services research as 
applicable. An ethically credible partnership strives 
to ensure that all investigators, staff, and other con-
tributing members of the partnership have adequate 
training in the responsible conduct of research will 
aid in fulfilling this principle.
  • Publication This principle arises from a concern 
regarding how research findings from academic-
industry partnerships are published and otherwise 
disseminated through the peer-reviewed literature 
and scientific and professional conferences [2, 38, 39, 
49, 52, 53]. Establishing publication committees and/
or guidelines at the beginning of each AHCIP will 
avoid most publication and authorship conflicts. An 
ethically credible partnership should formally estab-
lish the right for researchers to publish their results 
and should also encourage timely dissemination of its 
research findings.
  • Social, scientific, and industrial value It is accepted 
that partnerships should benefit the parties involved 
by satisfying the particular goals of each partner [2, 
3, 38, 54]. It is also accepted that benefits of AHCIPs 
should extend to science and society more generally. 
An ethically credible partnership should seek to cre-
ate value that, overall, will benefit others. Naturally, 
there are many types of benefits, but there should be 
agreement that the partnership is better positioned 
to advance these benefits than the individual partners 
alone. An ethically credible partnership will also be 
cognizant of the competitive nature of industry and 
academia and will seek to reasonably maintain any 
competitive advantage or expertise a partner might 
have in a given area of research.
  • Transparency This principle states that at a mini-
mum, the collaboration’s function and initial agree-
ment are known by and visible to relevant parties and 
the public [38]. Transparency is primarily achieved 
through establishing approaches to communicating 
internally and externally the commitment of the part-
ners to these principles and the procedures imple-
mented to fulfill them. Accordingly, partnerships 
with other companies and/or academic institutions 
should be disclosed to each partner.
In contrast with the principles, benchmarks are more 
concrete and intended to be framed as actionable steps 
that an organization could use to determine whether 
or not the principle was being satisfied. The combined 
document of principles and benchmarks constituted the 
ethics framework for our review. Benchmarks follow 
from or are developed in response to the more general 
principles. We did not establish a required number of 
benchmarks for each principle a priori but sought sim-
ply to provide as much guidance as we thought necessary 
to satisfy a given principle. Accordingly, some principles 
required more benchmarks than others to better specify 
what a particular principle necessitated. The resulting 
principles and benchmarks may be seen as the outcome 
of a process which sought to be exhaustive and compre-
hensive in its criteria for ethically credible AHCIPs.
We shared the ethics principles and benchmarks with 
RI leadership in a focus group setting before finalizing a 
document consisting of 9 principles and 23 benchmarks. 
(Table 1).
The benefits of using principles and benchmarks 
for building and assessing ethically credible 
partnerships
In their well-received paper that employed principles and 
benchmarks for ethically evaluating research in devel-
oping countries, Emanuel et al. described four potential 
benefits of identifying and using ethical benchmarks as 
tools for ethics evaluation: (1) benchmarks would allow 
for enhanced clarity in assessing which principle more 
stringently applies in a particular context; (2) the bench-
marks would characterize an explicit and systematic 
delineation of steps already being taken by conscientious 
researchers; (3) benchmarks would provide “more-spe-
cific and more-practical guidance… that can serve as a 
reminder and common reference for all those planning, 
conducting, and evaluating research”; and (4) bench-
marks could both narrow disagreements when principles 
conflict and make these disagreements less ethically wor-
risome [30].
We found many of the same benefits of benchmarks in 
our review of the RI AHCIP, and we believe similar ben-
efits may be experienced by other AHCIPs and AHCs 
who implement this document. Specifically, by agree-
ing to and targeting these benchmarks in advance, part-
ners can: (1) establish a practical and achievable floor 
for mutual expectations that can also flexibly accommo-
date the diversity of AHCIP structures; (2) provide more 
direct and specific guidance than principles alone; (3) 
embed ethical considerations throughout the partnership 
beyond conflicts of interest; and (4) prospectively assess 
ethical progress and identify possible deficiencies so pro-
cesses and outcomes can be improved.
Furthermore, we found that specification of the bench-
marks allowed a significant amount of versatility and 
adaptability for various methodologies of ethics review. 
For instance, the structure of the benchmarks readily 
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allowed for the generation of survey questions. As just 
one example, as part of a larger survey of RI scientists, 
we assessed the achievement of benchmark #2 by ask-
ing respondents to indicate whether they agreed or dis-
agreed (using a 5-point Likert scale) with the following 
statement, which is an analog to benchmark #2: “The… 
partnership ensures that all investigators involved in the 
partnership are given equal opportunity to submit pro-
posals for funding.”
Additionally, the principles and benchmarks were readily 
adaptable to the interview guide we used in a focus group 
early in the vetting process. While we did not employ other 
qualitative methods such as key informant interviews, we 
believe that the benchmarks document could also be used 
to generate questions and probes necessary for such an 
interview guide were it to be used by others.
We also found that the benchmark framework allows 
reviewers to identify areas of excellence and deficiency 
and then prescribe recommendations to address prob-
lems. For instance, while some principles and bench-
marks were not fully met by the RI AHCIP, we made 
specific recommendations that, if followed, could assist 
RI in meeting or exceeding the benchmarks in the future. 
[35] One illustrative recommendation was to “Increase 
transparency by providing more opportunities for inves-
tigators to become educated about the partnership, 
especially in areas where lack of understanding could 
potentially lead to an erosion of trust” [37]. This recom-
mendation was made based on our finding from a bench-
marks-based survey of all RI scientists that awareness 
of the partnership and its policies and procedures was 
lower than the acceptable ethical threshold we required. 
Indeed, Daniels et  al. found a similar benefit to using 
their benchmarks for fairness in health care reform, since 
their benchmarks assisted in identifying “places where 
proposed reforms were insufficiently detailed or vague 
Table 1 Ethical principles and benchmarks for ethically credible partnerships between ahcs and industry
Principles Benchmarks
Academic freedom 1. Promote investigator-initiated science and protect the ability to attract and maintain federal research 
support
2. Permit investigators to initiate or continue collaboration with any other qualified group, person, or 
entity
3. Ensure that all investigators involved in the partnership are given equal opportunity to submit propos-
als for funding
4. Avoid obligating faculty to work outside their own self-defined scientific area
Conflict of interest policy and management 5. Protect students, post-doctoral fellows and junior faculty involved in collaborative projects from exploi-
tation
6. Ensure that effective mechanisms exist to eliminate, control or manage conflicts of interest in the 
partnership
Intellectual property 7. Ensure all investigators and both partners retain their proprietary and intellectual property rights 
throughout and after the partnership
Data sharing, access 8. Ensure that data sharing arrangements are explicit and that all rights to access data are fairly negoti-
ated at the outset of the partnership
Effective governance 9. Establish parameters for what type of projects will and will not be funded (e.g. add-on projects, train-
ing, pilot studies)
10. Create ways to protect each party from an unexpected end to the partnership
11. Assess formally the efficiency, effectiveness, and achievements of the partnership on an annual basis
12. Ensure that clear, comprehensive, and efficient procedures exist for all governance entities of the 
partnership and are known to all investigators
Protection of human subjects 13. Ensure that all investigators, staff and other participants in the partnership have adequate training in 
the responsible conduct of research and related ethical issues
14. Ensure that all projects in the partnership aim to satisfy the highest ethical standards
Publication 15. Ensure the right of all researchers associated with the partnership to publish
16. Disseminate all research results at the conclusion of collaborative studies in a timely fashion
17. Ensure authorship follows ICMJE guidelines
Social, scientific, and industrial value 18. Maintain competitive advantage in the specified research domains
19. Structure the research to maximize potential benefit for communities and society
20. Structure the partnership to have the best chance of benefiting both partners and harming neither
Transparency 21. Widely publicize the partnership agreement and collaborative opportunities to the public and 
employees
22. Establish procedures for frequent and effective communication between partners
23. Ensure both partners are aware of other partnerships each may be involved in
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about mechanisms to reveal their effects; [and in reveal-
ing] problematic assumptions about how goals of reform 
would be achieved” [32]. A fuller description of the meth-
odology and recommendations we made are available 
elsewhere [37].
Assessing the efficacy of principles 
and benchmarks for ethically‑credible AHCIPs
We have described a proof of concept for assessing 
AHCIPs. We believe this framework could assist others 
in reviewing AHCIPs of varying structures and research 
foci. We also believe that applying this framework to 
other AHCIPs could assist in assessing the quality and 
efficacy of this framework so as to improve and refine it. 
In addition, there may be other ways to ascertain if this 
framework functions as an appropriate evaluative tool for 
AHCIPs. We hypothesize that this may be accomplished 
in at least three ways. First, the framework should be 
considered a success if parties setting up AHCIPs choose 
to incorporate it in their governance documents, as this 
would indicate that the benchmarks are taken seriously 
enough to be given legal or contractual weight. Secondly, 
the framework will be a success if others adopt the idea 
that AHCIPs have the potential to be ethically credible, 
as long as they meet the benchmarks. This alone would 
be a significant step given the adversarial disposition 
often taken against any industry involvement with aca-
demic institutions and research. Thirdly, the benchmarks 
would prove their merit if they were adopted by accred-
iting bodies such the AAHRP, or the Joint Commission, 
or by large not-for-profit entities that work in this area 
such as PhRMA or the University Industry Demonstra-
tion Partnership. It may take time for any or all three of 
these developments to occur, and there may well be other 
ways to validate this tool. We can report, as of this writ-
ing however, that the RI now incorporates these bench-
marks into all of its partnership contracts.
Conclusion
The impetus to discover, develop, and implement new 
therapies and medicines is now utilizing the translational 
science paradigm, although not without certain chal-
lenges [55]. Similarly, the incentive to leverage the com-
plementary strengths of industry and AHCs heightens 
the prospect of new models of mutually beneficial inter-
institutional collaboration. Jointly these developments 
raise the ethics stakes considerably. No longer is society’s 
moral concern limited to the lone researcher supported 
by an industry sponsor and the risks of biased influence 
associated with such support. Now, entire institutions are 
under the microscope—and rightly so. For this reason, 
the methods for managing conflict between academia 
and industry may no longer be attended to by disclosure 
requirements and other limitations on individual behav-
ior. It requires a new prescriptive approach that strikes 
a balance between the purported benefits of collabora-
tion and the broader risks, including reputational risks. 
Our recent experience suggests that a new approach to 
rigorous scrutiny of academic-industry partnerships is 
possible, though it is too early to tell whether it could 
meet the variety of needs in this area. More experience 
will be required to determine whether prospective ethi-
cal benchmarking supports both the benefits of AHCIPs 
and the highest standards of ethical integrity. We there-
fore encourage other AHCs contemplating or engaging 
in industry partnerships to use and improve our bench-
marks, and to further develop ethical approaches to the 
conduct of industry-funded research collaborations.
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